Focused ultrasound offers the potential to treat many cancers through non-invasively destroying malignant tissue or enhancing adjuvant therapy (e.g. chemotherapy or radiation).

The technology is approved in Europe and the U.S. to relieve the pain in patients with bone metastases. In addition, focused ultrasound systems to treat prostate cancer are approved in Europe and are currently under FDA review and may be commercially available in the U.S. soon.

four pillars module newFocused ultrasound is also approved in Europe to treat patients with breast, liver, pancreatic and kidney cancers and soft tissue tumors.

U.S. studies using focused ultrasound to non-invasively destroy tumors in the breast, thyroid, and prostate are expected to begin soon. 

In pediatric oncology, definitive studies in children are likely to be delayed until more studies in adults have been completed and analysed. However, a new clinical trial at Children's National Medical Center in Washington, DC is focused on patients (less than 30 years of age) with recurrent solid tumors for which there are no curative treatments. 

In addition, there is significant research activity around the globe assessing the potential of the technology to enhance the delivery and effectiveness of cancer drugs. 

Learn more about focused ultrasound for: 

ClinicalStage 35Bone Cancer
DC key
ClinicalStage 35Bone Metastases
ClinicalStage 35Brain Cancer
ClinicalStage 35Breast Cancer
ClinicalStage 35Kidney Cancer
ClinicalStage 35Liver Cancer
ClinicalStage 35Neuroblastoma
ClinicalStage 35Pancreatic Cancer
ClinicalStage 35Prostate Cancer
ClinicalStage 35Sacral Chordomas
ClinicalStage 35Soft Tissue Cancer
EarlyStages 35Bladder Cancer
EarlyStages 35Cervical Cancer
EarlyStages 35Colorectal Cancer
EarlyStages 35Esophageal Cancer
EarlyStages 35Head & Neck Cancer
EarlyStages 35Lung Cancer
EarlyStages 35Ovarian Cancer